Hill-Rom Holdings, Inc. (HRC) Income Statement Analysis

See more : Huadian Heavy Industries Co., Ltd. (601226.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Hill-Rom Holdings, Inc. (HRC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hill-Rom Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Hill-Rom Holdings, Inc. (HRC)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.hillrom.com

About Hill-Rom Holdings, Inc.

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	3.02B	2.88B	2.91B	2.85B	2.74B	2.66B	1.99B	1.69B	1.72B	1.63B	1.59B	1.47B	1.39B	1.51B	2.02B	1.96B	1.94B	1.83B	2.04B	1.76B	2.11B	2.10B	2.05B	2.00B	1.78B	1.68B	1.62B	1.58B	1.45B	1.43B	1.20B	1.11B	1.14B	884.30M	724.60M	641.10M	507.60M
Cost of Revenue	1.43B	1.41B	1.48B	1.45B	1.42B	1.40B	1.11B	906.20M	935.90M	879.60M	810.40M	753.00M	759.00M	838.20M	1.14B	1.11B	1.05B	921.00M	1.14B	1.01B	1.25B	1.27B	1.27B	1.17B	1.03B	908.00M	1.01B	939.20M	634.80M	646.60M	555.60M	508.90M	596.90M	410.40M	328.50M	286.90M	265.80M
Gross Profit	1.59B	1.48B	1.43B	1.39B	1.32B	1.26B	880.30M	779.90M	780.30M	754.70M	781.30M	716.60M	627.90M	669.50M	881.10M	849.80M	888.00M	908.00M	901.00M	748.00M	854.00M	826.00M	776.00M	834.00M	745.00M	776.00M	613.00M	637.80M	813.10M	783.20M	643.30M	597.70M	541.40M	473.90M	396.10M	354.20M	241.80M
Gross Profit Ratio	52.61%	51.20%	49.01%	48.95%	48.13%	47.34%	44.28%	46.25%	45.47%	46.18%	49.09%	48.76%	45.27%	44.41%	43.54%	43.29%	45.82%	49.64%	44.12%	42.57%	40.53%	39.41%	37.91%	41.68%	41.95%	46.08%	37.73%	40.44%	56.16%	54.78%	53.66%	54.01%	47.56%	53.59%	54.66%	55.25%	47.64%
Research & Development	144.90M	136.50M	139.50M	135.60M	133.70M	133.50M	91.80M	71.90M	70.20M	66.90M	63.80M	58.30M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	941.00M	891.50M	876.10M	853.30M	664.20M	548.30M	549.50M	496.40M	502.00M	474.60M	0.00	543.90M	604.40M	529.10M	604.00M	582.00M	573.00M	0.00	0.00	0.00	0.00	0.00	0.00	441.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	0.00	0.00	941.00M	891.50M	876.10M	853.30M	664.20M	548.30M	549.50M	496.40M	502.00M	474.60M	0.00	543.90M	604.40M	529.10M	604.00M	582.00M	573.00M	0.00	0.00	0.00	0.00	0.00	0.00	441.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Expenses	995.60M	929.40M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	517.30M	22.80M	-1.40M	3.10M	394.00M	6.00M	9.00M	780.00M	618.00M	582.00M	565.00M	606.00M	481.00M	99.00M	433.50M	481.80M	578.80M	593.80M	485.40M	460.20M	401.00M	338.50M	270.30M	240.60M	171.20M
Operating Expenses	1.14B	1.07B	1.08B	1.03B	1.01B	986.80M	756.00M	620.20M	619.70M	563.30M	565.80M	532.90M	517.30M	566.70M	603.00M	532.20M	998.00M	588.00M	582.00M	780.00M	618.00M	582.00M	565.00M	606.00M	481.00M	540.00M	433.50M	481.80M	578.80M	593.80M	485.40M	460.20M	401.00M	338.50M	270.30M	240.60M	171.20M
Cost & Expenses	2.57B	2.47B	2.56B	2.48B	2.43B	2.39B	1.86B	1.53B	1.56B	1.44B	1.38B	1.29B	1.28B	1.40B	1.75B	1.65B	2.05B	1.51B	1.72B	1.79B	1.87B	1.85B	1.84B	1.77B	1.51B	1.45B	1.45B	1.42B	1.21B	1.24B	1.04B	969.10M	997.90M	748.90M	598.80M	527.50M	437.00M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	65.60M	74.00M	89.60M	95.00M	88.90M	90.40M	18.40M	9.80M	9.50M	6.50M	8.50M	8.70M	10.40M	0.00	0.00	0.00	0.00	0.00	0.00	14.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	185.80M	178.80M	194.80M	196.50M	210.80M	209.00M	118.20M	106.40M	116.80M	111.70M	103.90M	99.70M	100.20M	112.80M	107.30M	108.80M	114.00M	108.00M	75.00M	71.00M	100.00M	89.00M	98.00M	149.00M	102.00M	99.00M	127.60M	97.50M	112.70M	115.30M	95.00M	94.00M	81.00M	68.80M	54.40M	49.30M	28.30M
EBITDA	554.20M	524.00M	493.00M	488.70M	484.00M	439.00M	202.60M	231.40M	270.30M	281.70M	271.90M	290.60M	-268.20M	253.80M	398.80M	447.50M	6.00M	338.00M	313.00M	50.00M	323.00M	329.00M	293.00M	442.00M	361.00M	332.00M	297.40M	242.30M	347.70M	297.30M	240.70M	220.40M	208.30M	189.20M	164.80M	149.20M	90.00M
EBITDA Ratio	18.36%	18.19%	16.96%	17.16%	17.64%	16.53%	10.19%	13.72%	15.75%	17.24%	17.08%	19.77%	-19.34%	16.83%	19.71%	22.80%	0.31%	18.48%	15.33%	2.85%	15.33%	15.70%	14.31%	22.09%	20.33%	19.71%	18.30%	15.36%	24.01%	20.79%	20.08%	19.92%	18.30%	21.40%	22.74%	23.27%	17.73%
Operating Income	447.60M	409.20M	344.50M	367.10M	310.80M	270.20M	124.30M	159.70M	160.60M	191.40M	215.50M	183.70M	110.60M	102.80M	278.10M	317.60M	-110.00M	320.00M	319.00M	-32.00M	236.00M	244.00M	211.00M	228.00M	264.00M	236.00M	179.50M	156.10M	234.30M	189.40M	157.90M	137.50M	140.40M	135.40M	125.80M	113.60M	70.60M
Operating Income Ratio	14.83%	14.20%	11.85%	12.89%	11.33%	10.18%	6.25%	9.47%	9.36%	11.71%	13.54%	12.50%	7.97%	6.82%	13.74%	16.18%	-5.68%	17.50%	15.62%	-1.82%	11.20%	11.64%	10.31%	11.39%	14.86%	14.01%	11.05%	9.90%	16.18%	13.25%	13.17%	12.43%	12.33%	15.31%	17.36%	17.72%	13.91%
Total Other Income/Expenses	-144.80M	-138.00M	-135.90M	-169.90M	-127.80M	-131.90M	-59.20M	-44.50M	-16.60M	-27.90M	-55.80M	-800.00K	-489.40M	-10.50M	13.40M	21.40M	-6.00M	-12.00M	-37.00M	-3.00M	-13.00M	-4.00M	-16.00M	65.00M	-5.00M	-3.00M	-9.70M	-11.30M	-12.70M	-18.10M	-12.20M	-11.10M	-13.10M	-15.00M	-15.40M	-13.70M	-8.90M
Income Before Tax	302.80M	271.20M	208.60M	197.20M	183.00M	138.30M	65.10M	115.20M	144.00M	163.50M	159.70M	182.90M	-378.80M	92.30M	291.50M	339.00M	-116.00M	308.00M	282.00M	-35.00M	223.00M	240.00M	195.00M	293.00M	259.00M	233.00M	169.80M	144.80M	221.60M	171.30M	145.70M	126.40M	127.30M	120.40M	110.40M	99.90M	61.70M
Income Before Tax Ratio	10.03%	9.41%	7.18%	6.92%	6.67%	5.21%	3.27%	6.83%	8.39%	10.00%	10.03%	12.45%	-27.31%	6.12%	14.40%	17.27%	-5.99%	16.84%	13.81%	-1.99%	10.58%	11.45%	9.53%	14.64%	14.58%	13.84%	10.45%	9.18%	15.30%	11.98%	12.15%	11.42%	11.18%	13.62%	15.24%	15.58%	12.16%
Income Tax Expense	54.30M	48.20M	56.40M	-55.20M	50.70M	15.50M	18.30M	54.60M	39.00M	42.70M	26.20M	56.90M	26.20M	25.20M	100.90M	117.50M	-20.00M	120.00M	100.00M	-25.00M	53.00M	86.00M	71.00M	109.00M	102.00M	93.00M	79.90M	55.30M	89.10M	65.80M	56.50M	50.70M	52.30M	50.70M	53.00M	49.40M	28.90M
Net Income	248.50M	223.00M	152.20M	252.40M	133.60M	124.10M	47.70M	60.60M	105.00M	120.80M	133.30M	125.30M	-405.00M	115.80M	190.60M	221.20M	-94.00M	110.00M	138.00M	-10.00M	170.00M	154.00M	124.00M	184.00M	157.00M	140.00M	89.90M	89.50M	145.90M	116.20M	89.20M	75.70M	75.00M	69.70M	57.40M	50.50M	32.80M
Net Income Ratio	8.23%	7.74%	5.24%	8.86%	4.87%	4.67%	2.40%	3.59%	6.12%	7.39%	8.37%	8.53%	-29.20%	7.68%	9.42%	11.27%	-4.85%	6.01%	6.76%	-0.57%	8.07%	7.35%	6.06%	9.20%	8.84%	8.31%	5.53%	5.68%	10.08%	8.13%	7.44%	6.84%	6.59%	7.88%	7.92%	7.88%	6.46%
EPS	3.72	3.32	2.25	3.73	2.03	1.89	0.73	1.06	1.79	1.99	2.16	2.00	-6.47	1.85	3.08	3.60	-1.52	1.77	2.22	-0.16	2.71	2.45	1.87	2.72	2.28	2.02	1.27	1.26	2.04	1.62	1.23	1.03	1.01	0.93	0.76	0.66	0.42
EPS Diluted	3.72	3.32	2.25	3.73	1.99	1.86	0.73	1.04	1.74	1.94	2.09	1.97	-6.47	1.85	3.07	3.59	-1.52	1.75	2.22	-0.16	2.71	2.45	1.87	2.72	2.28	2.01	1.27	1.26	2.04	1.62	1.23	1.03	1.01	0.93	0.76	0.66	0.42
Weighted Avg Shares Out	66.85M	67.21M	67.66M	67.61M	65.81M	65.71M	65.17M	57.44M	58.52M	60.80M	61.69M	62.79M	62.57M	62.43M	61.82M	61.45M	61.77M	62.24M	62.03M	62.70M	62.80M	62.90M	66.30M	67.60M	68.80M	69.47M	70.80M	71.30M	71.52M	71.73M	72.66M	73.22M	74.23M	74.59M	75.54M	77.10M	77.75M
Weighted Avg Shares Out (Dil)	66.85M	67.21M	67.66M	67.61M	67.23M	66.60M	65.17M	58.52M	60.25M	62.36M	63.90M	63.74M	62.58M	62.62M	62.12M	61.58M	61.77M	62.73M	62.18M	62.70M	62.80M	62.90M	66.30M	67.60M	68.80M	69.66M	70.80M	71.30M	71.52M	71.73M	72.66M	73.22M	74.23M	74.59M	75.54M	77.10M	77.75M

Baxter stock price forecast amid Hill-Rom acquisition rumours

August 29, 2021invezz.com

The Baxter (NYSE: BAX) stock price will be in the spotlight on Monday as rumours of its Hill-Rom acquisition resurfaced. The stock closed at $73.97 on Friday, which was about 17% below the highest point this year.

Baxter is in advanced talks to buy Hill-Rom for about $10B

August 29, 2021foxbusiness.com

Baxter International Inc. BAX 0.27% is in advanced talks to buy medical-equipment maker Hill-Rom Holdings Inc. HRC 0.96% for around $10 billion, according to people familiar with the matter.

SV Health Investors Announces Three Realizations in its Growth Equity Portfolio

August 19, 2021prnewswire.com

BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE: HRC) completed the acquisition of...

Hill-Rom (HRC) PSS Growth Solid Despite Tough Y/Y Comparison

August 18, 2021zacks.com

Hill-Rom's (HRC) recent launches, including the Helion Integrated Surgical System in the United States, buoy optimism.

Hill-Rom: Laying Comfortable

August 11, 2021seekingalpha.com

Hill-Rom: Laying Comfortable

HRC vs. SRDX: Which Stock Is the Better Value Option?

August 10, 2021zacks.com

HRC vs. SRDX: Which Stock Is the Better Value Option?

After trying to back out, Hill-rom will proceed with $376M deal to acquire Seattle's Bardy Diagnostics

August 6, 2021geekwire.com

Medical device company Hill-rom has called off its lawyers after initially backing out of a $375 million acquisition of Seattle startup Bardy Diagnostics.

What's Next For Hill-Rom Stock After An 18% Rise In A Month?

August 6, 2021forbes.com

The stock price of Hill-Rom Holdings, best known for its hospital beds and patient mobility solutions, has seen a rise of nearly 18% over the last twenty-one trading days, and it is also up a solid 40% year-to-date. The recent...